United States Antibiogram: Difference between revisions

Revision as of 06:45, 8 March 2014

Gram Positives

'	Penicillins	'	Anti-Staphylocccal Penicillins	'	'	Amino-Penicillins	'	'	Anti-Pseudomonal Penicillins	'	'	Carbapenems	'	'	'	'	'	Fluroquinolones	'	'	'	'	'	'	1st G Cephalosporins	2nd G. Cephalosporins	'	'	3rd/4th G. Cephalosporins	'	'	'	'	'	'	Oral 1st G. Cephalosporins	'	Oral 2nd G. Cephalosporins	'	'	Oral 3rd G. Cephalosporins	'	'	Aminoglycosides	'	'	'	'	Macrolides	'	'	Ketolide	Tetracyclines	'	Glycylcycline	Glyco/Lipoclycopeptides	'	'	'	'	'	Urinary Agents	'	Other	'	'	'	'	'
	Penicillin G	Penicillin V	Methicillin	Nafcillin/Oxacillin	Cloxacillin/Diclox.	AMP/Amox	Amox/Clav	AMP-Sulb	Ticarcillin	Ticar-Clav	Pip-Taxo	Piperacillin	Doripenem	Ertapenem	Imipenem	Meropenem	Aztreonam	Ciprofloxacin	Ofloxacin	Pefloxacin	Levofloxacin	Moxifloxacin	Gemifloxacin	Gatifloxacin	Cefazolin	Cefotetan	Cefoxitin	Cefuroxime	Cefotaxime	Cefizoxime	CefTRIAXone	Ceftobiprole	Ceftaroline	CefTAZidime	Cefepime	Cefadroxil	Cephalexin	Cefaclor/Loracarbef	Cefproxil	Cefuroxime axetil	Cefixime	Ceftibuten	Cefpodox/Cefdinir/Cefditoren	Gentamicin	Tobramycin	Amikacin	Chloramphenicol	Clindamycin	Erythromycin	Azithromycin	Clarithromycin	Telithromycin	Doxycycline	Minocycline	Tigecycline	Vancomycin	Teicoplanin	Telavancin	Fusidic Acid	Trimethoprim	TMP-SMX	Nitrofurantoin	Fosfomycin	Rifampin	Metronidazole	Quinupristin dalfoppristin	Linezolid	Daptomycin	Colistimethate
Strep. Group A, B, C, G	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	0	+/-	+/-	0	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	0	0	0	+	+	+/-	+/-	+/-	+	+/-	+	+	+	+	+	+/-	+	+	+		+	0	+	+	+	0
Strep. Pneumoniae	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	0	+/-	+/-	0	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+/-	+	0	0	0	+	+	+	+	+	+/-	+	+	+	+	+	+	+/-	+/-	+	+		+	0	+	+	+	0
Viridans strep	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+	+	+	+	0	0	0		+	+	+	+	+	+	+	+	+	+	+	+	+	+/-	+	+	+	+	0	+	+	0	+
Strep. milleri	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	0	0	0		+	+	+	+
Enterococcus faecalis	+	+	0	0	0	+	+	+	+/-	+/-	+	+	+/-	0	+	+/-	0	^^	^^	0	+	+	+	+	0	0	0	0	0	0	0	+	+	0	0	0	0	0	0	0	0	0	0	S	S	S	+/-	0	0	0	0	+/-	0	0	+	+	+	+	+	+	+	+	+	+/-	0	0	+	+	0
Enterococcus faecium	+/-	+/-	0	0	0	+	+	+	+/-	+/-	+/-	+/-	0	0	+/-	0	0	0	0	0	0	+/-	+/-	+/-																				S	0	0	+/-	0	0	0	0	0	0	0	+	+/-	+/-	+		0	0	+	+/-	0	0	+	+	+	0
Staph. aureus (MSSA)	0	0	+	+	+	0	+	+	0	+	+	0	+	+	+	+	0	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+/-	+	+	+	+	+	+	0	0	+	+	+	+	+/-	+	+/-	+	+	+	+/-	+/-	+	+	+	+	+	+/-	+	+		+	0	+	+	+	0
Staph. aureus (MRSA)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	+/-	+/-	+/-	0	0	0	0	0	0	0	+	+	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	+/-	+/-	+	+	+	+	+	+/-	+	+		+	0	+	+	+	0
Staph. aureus (CA-MRSA)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	+/-			+/-	+/-	+/-	+/-	0	0	0	0	0	0	0	+	+	0	0	0	0	0	0	0	0	0	0					+/-	+/-	+/-	+/-	+/-	+	+	+	+	+	+	+	+	+	+		+	0	+	+	+	0
Staph. Epidermidis	0	0	+	+	+	0	0	0	+/-	+/-	+	0	+	+	+	+	0	+	+	+	+	+	+	+	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+	+	+/-	+/-	+/-	+/-	+/-	+/-	+/-	0	0	+/-	+/-	+/-	+/-	0	0	+/-	0	0	0	0	0	+	+	+/-	+	+	+	+/-			+	0	+	+	+	0
C. jeikeium	0	0	0	0	0	0	0	0	0	0		0		0	0		0	0	0						0	0	0	0	0	0	0			0		0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	+	+	+	+	+	0	0	0		0	+	+	+	0
L. monocytogenes	+	0	0	0	0	+		+	+			+	+	+/-	+	+	0	+	0	0	+	+	+	+	0	0	0	0	0	0	0			0	0	0	0	0	0	0	0	0	0	S	S	S	+		+	+	+	+	+	+	+	+	+	+		+	+			+	0	+	+	+/-	0

Key

+ usually effective clinically or >60% susceptible
+/- clinical trials lacking or 30-60% susceptible
0 not effective clinically or <30% susceptible
blank data not available

Source

Sanford Guide to Antimicrobial Therapy 2010

Authors:

@@ Line 104: / Line 104: @@
 *'''0''' not effective clinically or <30% susceptible
 *'''blank''' data not available
+{{Clinically Relevant Bacteria}}
+{{Clinically Utilized Antibiotics}}
 ==See Also==